Short answer
Astrana Health, Inc. (ASTH) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Updated corporate presentation dated September 15, 2026 for conference and investor meetings.
Astrana Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation dated September 15, 2026 for conference and investor meetings
- Exhibit 99.1 contains the substantive company disclosures and presentation materials
- Company disclaims any obligation to update the presentation
- Information furnished under Regulation FD, not formally filed under Exchange Act Section 18
Item EX-99.1 · Exhibit EX-99.1
- FY2026 revenue guidance of $3.8–4.1B, implying continued rapid scale from $3.18B in FY2025
- Adjusted EBITDA guidance raised to $255–280M, above $205.4M in FY2025
- Free cash flow guidance of $105–132.5M, versus $104.5M in FY2025
- Q2 revenue $972.5M and adjusted EBITDA $68.9M, while YTD free cash flow reached $92.9M
- Platform scale: ~1.5M value-based members, 20,000+ providers, and 16 markets, supporting operating leverage from AI deployment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Astrana Health, Inc. 8-K filings
Get the next ASTH 8-K as it lands
Follow ASTH for push alerts, or ask the research agent what this filing means.